ALFA FinderBSE filing, NSE: SUNPHARMA. Summary written from the filing by ALFA Finder's alert engine.
Sun Pharmaceutical Industries Ltd: key numbers
- Share price
- ₹1,915.00
- Market cap
- ₹4,59,473 Cr
- Revenue (annual)
- ₹58,462 Cr
- Net profit (annual)
- ₹11,479 Cr
- P/E (TTM)
- 41.9×Sector 48.6×
- Promoter holding
- 52.68%-1.80% QoQ
- FII holding
- 14.36%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sun Pharmaceutical Industries Ltd
All →Sun Pharmaceutical Industries Price Movement Clarification
Sun Pharma said a 30 October 2026 news report concerned August 2026 developments, not new events. It confirmed no undisclosed material information explains the share price movement.
Sun Pharmaceutical Industries Annual General Meeting
Sun Pharma's postal ballot passed all seven special resolutions, including ESOP 2026 approval and borrowing and security limits. No monetary transaction is stated.
Sun Pharmaceutical Industries Earnings Call Transcript: Key Takeaways
Sun Pharma delivered resilient double-digit revenue growth despite U.S. specialty headwinds, masking underlying margin pressure from lower Lenalidomide sales.
Sun Pharmaceutical Industries Other Announcement
Sun Pharma's board appointed Deloitte as Statutory Auditors under mandatory rotation, effective from the FY 2026-27 AGM. This follows SRBC & CO's second five-year term completion.
Sun Pharmaceutical Industries Q2 FY27 Results: Net Profit ₹1,995 Cr, Down 36.2% YoY
Sun Pharmaceutical Industries Ltd reported revenue from operations of ₹16,199 Cr (+11.9% YoY) and net profit of ₹1,995 Cr (-36.2% YoY) for Q2 FY27.
- Key figure
- Net profit ₹1,995 Cr · -36.2% YoY
Sun Pharmaceutical Industries Regulatory Approval
Sun Pharma gained US FDA approval for ILUMYA in adults with active psoriatic arthritis. The approval extends the drug's psoriasis use, with no financial value stated.
Other legal & regulatory announcements
All →Saurashtra Cements Legal & Regulatory
Saurashtra Cement received a GST show cause notice under Section 74(5) for non-payment of GST on royalty and other charges for FY 2022-23. The total demand is Rs. 1,91,48,238, which the company disputes and will contest.
- Value
- ₹1.91 Cr
Tata Power Company Legal & Regulatory
Tata Power discloses Singapore court developments in its Kleros arbitration, including share attachment notices to two subsidiaries. Detailed appeal submissions are due November 23, 2026.
Baroda Rayon Corporation Legal & Regulatory
Baroda Rayon's ITAT Mumbai allowed both its quantum and penalty appeals for AY 2014-15, deleting a ₹12.15 Crore Section 68 addition and a ₹4.13 Crore penalty. The filing updates a pending tax litigation disclosed earlier.
- Value
- ₹12.15 Cr
HD Fire Protect Legal & Regulatory
HD Fire Protect received a GST order dropping a ₹7.10 Crore show-cause demand for FY 2022-23. The order has no financial or operational impact on the company.
- Value
- ₹7.10 Cr
EKI Energy Services Legal & Regulatory
EKI Energy's counterparty Vitol terminated an emission reduction agreement and invoked a USD 10 million bank guarantee. The company disputes the default claim and plans arbitration.
- Value
- ₹94.00 Cr
Mangalore Refinery And Petrochemicals Legal & Regulatory
MRPL received a Customs order demanding ₹1,39,871 plus interest and penalty for 2021 tariff misclassification. The company is considering challenging the order after depositing the money.
- Value
- ₹0.01 Cr